Saudi Arabia is accelerating its efforts to localize pharmaceutical manufacturing by preparing to introduce 11 locally produced vaccines into the domestic market, a major step toward strengthening drug security and reducing reliance on imports as part of the Kingdom’s Vision 2030 healthcare and industrial strategy.
According to informed sources, the vaccines are expected to cover approximately 70% of the Kingdom’s demand for essential immunizations, including seasonal influenza vaccines, with the first products entering the market next year while production capacity continues to expand through 2027.
Strengthening Pharmaceutical Security
The initiative forms part of Saudi Arabia’s broader ambition to become a regional hub for pharmaceutical and biotechnology manufacturing through strategic partnerships with leading global drug manufacturers and advanced technology transfer programs.
The strategy aims to ensure a stable supply of critical medicines and vaccines while improving resilience against disruptions in global supply chains, a priority highlighted by the COVID-19 pandemic.
Eleven Vaccines Planned by 2027
Dr. Khaled Al-Mousa, founder and chairman of the Biotechnology Localization Group, said the Kingdom plans to manufacture 11 essential vaccines capable of meeting around 70% of national demand by the fourth quarter of 2027.
He explained that technology transfer will initially be carried out with international partners before gradually achieving full localization of the entire manufacturing process, including production, research, and development.
The initiative also seeks to increase Saudi workforce participation in the biotechnology sector to 80% through specialized national training programs designed to prepare highly skilled professionals for the industry.
A Rapidly Expanding Pharmaceutical Market
Saudi Arabia’s pharmaceutical market was valued at approximately $10.5 billion in 2024 and is projected to grow to more than $16.5 billion by 2032, representing a compound annual growth rate of over 6%.
The expansion reflects rising healthcare demand, increased investment in life sciences, and continued government support for domestic pharmaceutical production.
Growing Manufacturing Capacity
According to the Ministry of Industry and Mineral Resources, the Kingdom currently has 206 pharmaceutical and medical device manufacturing facilities, including 56 licensed pharmaceutical factories registered with the Saudi Food and Drug Authority, representing investments exceeding SAR 7 billion.
The domestic pharmaceutical market has also expanded significantly, growing from approximately $8 billion in 2019 to around $10 billion annually by 2023, while dependence on imported medicines declined from 80% to 70%.
Building a Regional Biotechnology Hub
The vaccine localization program is part of Saudi Arabia’s long-term strategy to establish itself as a leading regional center for pharmaceuticals and biotechnology by supporting innovation, expanding research and development, attracting global investment, and strengthening national healthcare capabilities.
The initiative is expected to enhance long-term pharmaceutical security while contributing to economic diversification and the development of a knowledge-based life sciences industry.
